Category: ODD/BTA/FTA Status Region: North America · United States Company: Neurocrine Biosciences Inc

FDA grants orphan drug status to UniQures Huntingtons Disease treatment

By, Admin 1 min read
Share
FDA grants orphan drug status to UniQures Huntingtons Disease treatment
Dutch biotech UniQure has won orphan drug designation (ODD) for its investigational treatment for Huntington

Found this useful? Share it with your team.

Welcome Back Sign in to Continue

Don't Have an Account? Sign Up!
Forgot Password?

Create your Account!

Don't Have an Account? Sign Up!